Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Conditions
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Trial Timeline
Mar 8, 2012 → Apr 8, 2024
NCT ID
NCT01550003About Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP)
Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP) is a phase 3 stage product being developed by UCB for Polyarticular-course Juvenile Idiopathic Arthritis (JIA). The current trial status is completed. This product is registered under clinical trial identifier NCT01550003. Target conditions include Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01550003 | Phase 3 | Completed |